Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Fuji
Accenture
McKinsey
Deloitte
UBS
Express Scripts
QuintilesIMS
Queensland Health
Cerilliant

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,337,824

« Back to Dashboard

Which drugs does patent 8,337,824 protect, and when does it expire?

Patent 8,337,824 protects VELTASSA and is included in one NDA.

This patent has thirty-six patent family members in twenty countries.
Summary for Patent: 8,337,824
Title:Linear polyol stabilized polyfluoroacrylate compositions
Abstract: The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract.
Inventor(s): Albrecht; Detlef (Saratoga, CA), Burdick; Michael (Los Altos, CA), Chang; Han-Ting (Livermore, CA), Charmot; Dominique (Campbell, CA), Chidambaram; Ramakrishnan (Pleasanton, CA), Connor; Eric (Los Gatos, CA), Halfon; Sherin (Palo Alto, CA), Huang; I-Zu (Mountain View, CA), Liu; Mingjun (Campbell, CA), Mills; Jonathan (San Jose, CA), Struver; Werner (Leverkusen, DE)
Assignee: Relypsa, Inc. (Santa Clara, CA)
Application Number:12/545,810
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Use;

Drugs Protected by US Patent 8,337,824

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERKALEMIA ➤ Sign Up
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-002 Oct 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERKALEMIA ➤ Sign Up
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERKALEMIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,337,824

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2365988 ➤ Sign Up
European Patent Office 2957286 ➤ Sign Up
Spain 2545887 ➤ Sign Up
United Kingdom 201104561 ➤ Sign Up
United Kingdom 2475657 ➤ Sign Up
United Kingdom 201222749 ➤ Sign Up
United Kingdom 2495426 ➤ Sign Up
United Kingdom 201222750 ➤ Sign Up
United Kingdom 2495427 ➤ Sign Up
United Kingdom 201222752 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Medtronic
QuintilesIMS
Boehringer Ingelheim
Express Scripts
Harvard Business School
UBS
Mallinckrodt
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot